logo
  

Albemarle Q1 Profit Beats Street

Albemarle Corp. (ALB) Wednesday reported a first-quarter profit that trumped Wall Street estimates by a penny, driven by a more-than-expected increase in revenues.

Albemarle's first-quarter net income rose to $133.6 million or $1.26 per share from $131.76 million or $1.18 per share last year.

Adjusted earnings for the quarter dropped to $1.23 per share from $1.30 per share last year. On average, 16 analysts polled by Thomson Reuters estimate earnings of $1.22 per share for the quarter. Analysts' estimates typically exclude one-time items.

First-quarter sales rose 6% to $832.1 million from $821.6 million last year. Analysts had a consensus revenue estimate of $817.04 million fort he quarter.

CEO Luke Kissam said, "Lithium pricing was up year-over-year, while Catalysts and Bromine Specialties performed well, with both benefiting from increases in volume and price. We remain confident in our expectations for the full year, and committed to our long-term strategy that positions us for continued growth."

Lithium sales dropped 2.1% to $291.9 million due to lower sales volume driven by the impact of a rain event in Chile. Bromine Specialties sales rose 10.4% to $249.1 million, while catalysts sales slipped 3.5% to $251.6 million.

Looking forward to full year, the company confirmed its adjusted earnings outlook of $6.10 to $6.50 per share and revenues of $3.65 to $3.85 billion. Analysts currently estimate earnings of $6.21 per share and revenues of $3.68 billion for the year.

ALB closed Wednesday's trading at $72.58, down $3.27 or 4.31%, on the NYSE. The stock, however, gained $2.14 or 2.95% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
RELATED NEWS
Follow RTT